Form 4 for PCRX Pacira BioSciences, Inc.
Accepted 2026-04-22 20:03:15 ET · period of report 2026-04-20 · accession 0001628280-26-026669 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-04-22 20:03 | 2026-04-20+ | PCRX | Cross Shawn | CFO | M - OptEx | $16.45 | +12.1K | 106.8K | +13% | +$198.4K |
| DMT | 2026-04-22 20:03 | 2026-04-20+ | PCRX | Cross Shawn | CFO | S - Sale+OE | $25.09 | -12.1K | 105.3K | -10% | -$302.6K |
| DMT | 2026-04-22 20:03 | 2026-04-20+ | PCRX | Cross Shawn | CFO | M - OptEx | $0.00 | -12.1K | 162.9K | -7% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-20 | M | A | 7,714 | $16.45 | 113,055 | D | — | — | (F1) The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. |
| 2 | Common | Common Stock | 2026-04-20 | S | D | 7,714 | $25.14 | 105,341 | D | — | — | (F1) The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.31, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 2 and 3. |
| 3 | Common | Common Stock | 2026-04-21 | M | A | 2,845 | $16.45 | 108,186 | D | — | — | (F1) The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. |
| 4 | Common | Common Stock | 2026-04-21 | S | D | 2,845 | $25.01 | 105,341 | D | — | — | (F1) The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.04, inclusive. |
| 5 | Common | Common Stock | 2026-04-22 | M | A | 1,500 | $16.45 | 106,841 | D | — | — | (F1) The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. |
| 6 | Common | Common Stock | 2026-04-22 | S | D | 1,500 | $25.01 | 105,341 | D | — | — | (F1) The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.04, inclusive. |
| 7 | Derivative | Stock Option (Right to Buy) | 2026-04-20 | M | D | 7,714 | $0.00 | 167,286 | D | $16.45 · — to 2034-11-04 | 7,714 Common Stock | (F1) The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. (F4) The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. (F1) The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. |
| 8 | Derivative | Stock Option (Right to Buy) | 2026-04-21 | M | D | 2,845 | $0.00 | 164,441 | D | $16.45 · — to 2034-11-04 | 2,845 Common Stock | (F1) The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. (F4) The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. (F1) The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. |
| 9 | Derivative | Stock Option (Right to Buy) | 2026-04-22 | M | D | 1,500 | $0.00 | 162,941 | D | $16.45 · — to 2034-11-04 | 1,500 Common Stock | (F1) The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. (F4) The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. (F1) The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. |